Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) are considered primary drugs for the secondary prevention of myocardial infarction (MI), and angiotensin receptor blockers (ARBs) are used when ACEIs cannot be tolerated. However, it is unclear whether ACEIs or ARBs are more appropriate first-line drugs in hypertensive patients with MI or heart failure (HF). The present study aimed to compare the effects of ACEIs and those of ARBs in these patients. Sixty randomized controlled trails (RCTs) that compared the effects of ACEIs and ARBs in patients with MI or HF were extracted by searching PubMed/MEDLINE, Cochrane Database, and the Medical Central Journal database according to the PRISMA guidelines. We finally selected six eligible RCTs and identified three systematic reviews and meta-analyses. The proportion of hypertensive patients ranged from 36 to 69%. Meta-analyses were performed for recurrence or new onset of MI (risk ratio 0.97 [95% confidence interval: 0.88, 1.06]), hospitalization for HF (0.98 [0.84, 1.14]), cardiovascular or total mortality (0.98 [0.91, 1.05]), cardiovascular events or stroke (1.02 [0.94, 1.11]), and adverse events (1.40 [1.11, 1.77]). There were no significant differences between ACEIs and ARBs for all outcomes, except adverse events. Study discontinuation owing to adverse events was significantly more common with ACEIs than with ARBs. Among hypertensive patients with MI or HF, it appears desirable to select the most appropriate drugs, ACEIs or ARBs, in each case by considering the function level, patient background, comorbidity presence, blood pressure target, drug price and other such factors comprehensively in addition to considering tolerability.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: where are we now? Circ J. 2013;77:2226–31.

    Article  Google Scholar 

  2. 2.

    Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951–7.

    CAS  Article  Google Scholar 

  3. 3.

    Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.

    Article  Google Scholar 

  4. 4.

    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;00:1–98.

    Google Scholar 

  5. 5.

    Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951–8.

    Article  Google Scholar 

  6. 6.

    Group JCSJW. Guidelines for secondary prevention of myocardial infarction (JCS 2011). Circ J. 2013;77:231–48.

    Article  Google Scholar 

  7. 7.

    ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669–85.

  8. 8.

    GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115–22.

  9. 9.

    Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.

    CAS  Article  Google Scholar 

  10. 10.

    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–8.

  11. 11.

    Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–6.

    CAS  Article  Google Scholar 

  12. 12.

    Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.

    Article  Google Scholar 

  13. 13.

    Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.

    Article  Google Scholar 

  14. 14.

    Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.

    Article  Google Scholar 

  15. 15.

    Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843–8.

    CAS  Article  Google Scholar 

  16. 16.

    Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–81.

    CAS  Article  Google Scholar 

  17. 17.

    Dickstein K, Kjekshus J, Group OSCotOS. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.

    CAS  Article  Google Scholar 

  18. 18.

    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

    CAS  Article  Google Scholar 

  19. 19.

    Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.

    CAS  Article  Google Scholar 

  20. 20.

    Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7.

    CAS  Article  Google Scholar 

  21. 21.

    Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviewes and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.

  22. 22.

    Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;4:CD003040.

  23. 23.

    Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096.

  24. 24.

    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  Google Scholar 

  25. 25.

    Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.

    CAS  Article  Google Scholar 

  26. 26.

    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  Google Scholar 

  27. 27.

    Suzuki H, Geshi E, Nanjyo S, Nakano H, Yamazaki J, Sato N, et al. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J. 2009;73:918–24.

    Article  Google Scholar 

  28. 28.

    Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609–17.

    CAS  Article  Google Scholar 

  29. 29.

    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.

    CAS  Article  Google Scholar 

  30. 30.

    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.

    CAS  Article  Google Scholar 

  31. 31.

    Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan Study I. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5:669–77.

    CAS  Article  Google Scholar 

  32. 32.

    McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–64.

    CAS  Article  Google Scholar 

  33. 33.

    Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893–1900.

    Article  Google Scholar 

  34. 34.

    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Toshio Ohtsubo or Rei Shibata.

Ethics declarations

Conflict of interest

TO received honoraria from Sanwa Kagaku Kenkyusho. RS received honoraria from Medtoronic, Boehringer Ingelheim, Eli Lilly, and Otsuka Pharmaceutical Factory. HK received honoraria from Daiichi Sankyo Co., Mitsubishi Tanabe Pharma Co., Shionogi & Co., Dainippon Sumitomo Pharma Co., and Takeda Pharmaceutical Co. TK received honoraria from Daiichi Sankyo and research funding from Daiichi Sankyo, Takeda Pharmaceutical, Astellas Pharma, Chugai Pharmaceutical, MSD, Boehringer Ingelheim, EA Pharma, Sanofi Aventis, Pfizer, Kissei Pharmaceutical, Kyowa Hakko Kirin, Asahi Kasei Medical, Otsuka Pharmaceutical, Torii Pharmaceutical, and Bayer.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ohtsubo, T., Shibata, R., Kai, H. et al. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis. Hypertens Res 42, 641–649 (2019). https://doi.org/10.1038/s41440-018-0167-5

Download citation

Keywords

  • angiotensin-converting enzyme inhibitors
  • angiotensin receptor blockers
  • heart failure
  • hypertension
  • meta-analysis
  • myocardial infarction
  • systematic review

Further reading

  • Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases

    • Ilkay Erdogan Orhan

    Current Medicinal Chemistry (2019)

  • The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)

    • Satoshi Umemura
    • , Hisatomi Arima
    • , Shuji Arima
    • , Kei Asayama
    • , Yasuaki Dohi
    • , Yoshitaka Hirooka
    • , Takeshi Horio
    • , Satoshi Hoshide
    • , Shunya Ikeda
    • , Toshihiko Ishimitsu
    • , Masaaki Ito
    • , Sadayoshi Ito
    • , Yoshio Iwashima
    • , Hisashi Kai
    • , Kei Kamide
    • , Yoshihiko Kanno
    • , Naoki Kashihara
    • , Yuhei Kawano
    • , Toru Kikuchi
    • , Kazuo Kitamura
    • , Takanari Kitazono
    • , Katsuhiko Kohara
    • , Masataka Kudo
    • , Hiroo Kumagai
    • , Kiyoshi Matsumura
    • , Hideo Matsuura
    • , Katsuyuki Miura
    • , Masashi Mukoyama
    • , Satoko Nakamura
    • , Takayoshi Ohkubo
    • , Yusuke Ohya
    • , Takafumi Okura
    • , Hiromi Rakugi
    • , Shigeyuki Saitoh
    • , Hirotaka Shibata
    • , Tatsuo Shimosawa
    • , Hiromichi Suzuki
    • , Shori Takahashi
    • , Kouichi Tamura
    • , Hirofumi Tomiyama
    • , Takuya Tsuchihashi
    • , Shinichiro Ueda
    • , Yoshinari Uehara
    • , Hidenori Urata
    •  & Nobuhito Hirawa

    Hypertension Research (2019)

Search